164 related articles for article (PubMed ID: 37216758)
1. Treatment of opioid use disorder in Ukraine during the first year of the Russia-Ukraine war: Lessons learned from the crisis.
Morozova O; Ivanchuk I; Gvozdetska O; Nesterova O; Skala P; Kuzin I; Dumchev K
Int J Drug Policy; 2023 Jul; 117():104062. PubMed ID: 37216758
[TBL] [Abstract][Full Text] [Related]
2. Qualitative exploration of the early experiences of opioid use disorder patients from private clinics after Russia's invasion of Ukraine in five major cities in Ukraine.
Mazhnaya A; Meteliuk A; Pykalo I; Altice FL
Front Public Health; 2023; 11():1238188. PubMed ID: 38162610
[TBL] [Abstract][Full Text] [Related]
3. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
[TBL] [Abstract][Full Text] [Related]
4. Responding to health policy recommendations on managing opioid use disorder during Russia's invasion of Ukraine: Divergent responses from the frontline to the west.
Ivasiy R; Galvez de Leon SJ; Meteliuk A; Fomenko T; Pykalo I; Bromberg DJ; Madden LM; Farnum SO; Islam Z; Altice FL
Front Public Health; 2022; 10():1044677. PubMed ID: 36711398
[No Abstract] [Full Text] [Related]
5. Re-examining provider perceptions of best pre-war practices: what elements can help opiate agonist therapy programs in Ukraine successfully survive the crisis?
Dellamura P; Meteliuk A; Fomenko T; Rozanova J
Front Public Health; 2023; 11():1259488. PubMed ID: 38239802
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Russian invasion on opioid agonist therapy programs in Ukraine: A qualitative study.
Dubov A; Basenko A; Dymaretskyi O; Shoptaw S
Drug Alcohol Depend; 2024 Feb; 255():111069. PubMed ID: 38159338
[TBL] [Abstract][Full Text] [Related]
7. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
8. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
9. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
10. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
11. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
12. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
13. Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.
Button D; Cook R; King C; Khuyen TT; Kunkel L; Bart G; Thuy DT; Nguyen DB; Blazes CK; Giang LM; Korthuis PT
Int J Drug Policy; 2022 Feb; 100():103503. PubMed ID: 34768124
[TBL] [Abstract][Full Text] [Related]
14. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
15. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
16. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
[TBL] [Abstract][Full Text] [Related]
17. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
18. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
[TBL] [Abstract][Full Text] [Related]
19. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
20. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
